PL3678673T3 - Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankach - Google Patents
Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankachInfo
- Publication number
- PL3678673T3 PL3678673T3 PL18792572.2T PL18792572T PL3678673T3 PL 3678673 T3 PL3678673 T3 PL 3678673T3 PL 18792572 T PL18792572 T PL 18792572T PL 3678673 T3 PL3678673 T3 PL 3678673T3
- Authority
- PL
- Poland
- Prior art keywords
- modulation
- tissue
- expression
- compositions
- processes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 229920002477 rna polymer Polymers 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1714430.4A GB201714430D0 (en) | 2017-09-07 | 2017-09-07 | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| US201862632056P | 2018-02-19 | 2018-02-19 | |
| PCT/US2018/049772 WO2019051100A1 (en) | 2017-09-07 | 2018-09-06 | COMPOSITIONS AND METHODS FOR TARGETED CODING ADMINISTRATION, EXPRESSION AND MODULATION OF RIBONUCLEIC ACIDS IN TISSUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3678673T3 true PL3678673T3 (pl) | 2023-07-10 |
Family
ID=60117350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18792572.2T PL3678673T3 (pl) | 2017-09-07 | 2018-09-06 | Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankach |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11359212B2 (https=) |
| EP (2) | EP3678673B1 (https=) |
| JP (4) | JP2020533411A (https=) |
| KR (1) | KR102741572B1 (https=) |
| CN (1) | CN111212650A (https=) |
| AU (1) | AU2018328289B2 (https=) |
| CA (1) | CA3074293A1 (https=) |
| ES (1) | ES2942890T3 (https=) |
| GB (1) | GB201714430D0 (https=) |
| MX (2) | MX2020002568A (https=) |
| PL (1) | PL3678673T3 (https=) |
| PT (1) | PT3678673T (https=) |
| RU (1) | RU2020112990A (https=) |
| WO (1) | WO2019051100A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| IL295724A (en) | 2020-02-21 | 2022-10-01 | Combined Therapeutics Inc | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| IL300247A (en) | 2020-07-31 | 2023-03-01 | Combined Therapeutics Inc | Compositions and methods for improving vaccination |
| CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
| CN113444744A (zh) * | 2021-06-28 | 2021-09-28 | 北京鼎成肽源生物技术有限公司 | 一种用于基因编辑NK细胞的mRNA模板及构建方法、mRNA的体外转录方法和应用 |
| CN114107347B (zh) * | 2021-11-24 | 2022-10-28 | 中国人民解放军空军军医大学 | 一种基于具有按需抗炎功能、装载炎症响应型mRNA的工程化外泌体及其构建方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004529607A (ja) * | 2000-09-15 | 2004-09-30 | キュラジェン コーポレイション | ヒトポリヌクレオチドおよびそれによってコードされるポリペプチド |
| US7264814B2 (en) * | 2001-05-09 | 2007-09-04 | M's Science Corporation | Composition and method for treating cancer using herpes virus |
| EP1644492B1 (en) * | 2003-06-18 | 2009-01-07 | Genelux Corporation | Modified recombinant vaccinia viruses, uses thereof |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| ES2646630T3 (es) | 2008-11-07 | 2017-12-14 | Massachusetts Institute Of Technology | Lipidoides aminoalcohólicos y usos de los mismos |
| WO2011101912A1 (ja) * | 2010-02-19 | 2011-08-25 | 国立大学法人東京大学 | 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物 |
| RU2648950C2 (ru) * | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| WO2014081507A1 (en) * | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| AU2014337156A1 (en) * | 2013-10-18 | 2016-05-12 | Modernatx, Inc. | Compositions and methods for tolerizing cellular systems |
| CN106068326B (zh) * | 2013-10-28 | 2021-06-18 | 联邦高等教育系统-匹兹堡大学 | 溶瘤性hsv载体 |
| EP3068425B1 (en) * | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| JP2017523777A (ja) * | 2014-07-17 | 2017-08-24 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | ポリヌクレオチドの末端修飾 |
| WO2016040395A1 (en) * | 2014-09-08 | 2016-03-17 | Massachusetts Institute Of Technology | Rna-based logic circuits with rna binding proteins, aptamers and small molecules |
| WO2016049512A1 (en) * | 2014-09-26 | 2016-03-31 | University Of Massachusetts | Rna-modulating agents |
| EP3233132A4 (en) * | 2014-12-19 | 2018-06-27 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| ES2861450T3 (es) * | 2015-07-20 | 2021-10-06 | Virttu Biologics Ltd | Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer |
| AU2016336344A1 (en) * | 2015-10-05 | 2018-04-19 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| AU2016355468B2 (en) * | 2015-11-20 | 2022-12-15 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| RU2749050C2 (ru) * | 2016-01-27 | 2021-06-03 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| SG11201903674YA (en) | 2016-10-26 | 2019-05-30 | Modernatx Inc | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| EP3558356A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| JP2021514190A (ja) | 2018-02-19 | 2021-06-10 | コンバインド セラピューティクス インコーポレイテッドＣｏｍｂｉｎｅｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | コード化リボ核酸の器官保護発現および調節のための組成物および方法 |
| IL295724A (en) * | 2020-02-21 | 2022-10-01 | Combined Therapeutics Inc | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
-
2017
- 2017-09-07 GB GBGB1714430.4A patent/GB201714430D0/en not_active Ceased
-
2018
- 2018-09-06 EP EP18792572.2A patent/EP3678673B1/en active Active
- 2018-09-06 KR KR1020207009937A patent/KR102741572B1/ko active Active
- 2018-09-06 PT PT187925722T patent/PT3678673T/pt unknown
- 2018-09-06 CA CA3074293A patent/CA3074293A1/en active Pending
- 2018-09-06 RU RU2020112990A patent/RU2020112990A/ru unknown
- 2018-09-06 CN CN201880066146.2A patent/CN111212650A/zh active Pending
- 2018-09-06 AU AU2018328289A patent/AU2018328289B2/en active Active
- 2018-09-06 PL PL18792572.2T patent/PL3678673T3/pl unknown
- 2018-09-06 EP EP23153161.7A patent/EP4218770A3/en active Pending
- 2018-09-06 WO PCT/US2018/049772 patent/WO2019051100A1/en not_active Ceased
- 2018-09-06 MX MX2020002568A patent/MX2020002568A/es unknown
- 2018-09-06 JP JP2020536493A patent/JP2020533411A/ja active Pending
- 2018-09-06 ES ES18792572T patent/ES2942890T3/es active Active
-
2019
- 2019-02-19 MX MX2020008606A patent/MX2020008606A/es unknown
-
2020
- 2020-03-06 US US16/811,504 patent/US11359212B2/en active Active
-
2022
- 2022-03-28 US US17/706,522 patent/US12195746B2/en active Active
-
2023
- 2023-08-03 JP JP2023127023A patent/JP2023159160A/ja active Pending
-
2024
- 2024-02-02 JP JP2024015220A patent/JP2024059656A/ja active Pending
- 2024-05-16 JP JP2024080380A patent/JP2024122983A/ja active Pending
- 2024-12-17 US US18/984,898 patent/US20250129383A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020112990A (ru) | 2021-10-07 |
| MX2020002568A (es) | 2020-09-18 |
| EP3678673B1 (en) | 2023-01-25 |
| AU2018328289B2 (en) | 2025-07-10 |
| CN111212650A (zh) | 2020-05-29 |
| JP2023159160A (ja) | 2023-10-31 |
| KR20200104282A (ko) | 2020-09-03 |
| JP2024059656A (ja) | 2024-05-01 |
| RU2020130763A (ru) | 2022-03-21 |
| RU2020130763A3 (https=) | 2022-03-22 |
| EP3678673A1 (en) | 2020-07-15 |
| ES2942890T3 (es) | 2023-06-07 |
| RU2020112990A3 (https=) | 2022-03-05 |
| US11359212B2 (en) | 2022-06-14 |
| MX2020008606A (es) | 2020-09-21 |
| US20220220506A1 (en) | 2022-07-14 |
| US12195746B2 (en) | 2025-01-14 |
| EP4218770A2 (en) | 2023-08-02 |
| AU2018328289A1 (en) | 2020-03-19 |
| GB201714430D0 (en) | 2017-10-25 |
| JP2024122983A (ja) | 2024-09-10 |
| US20250129383A1 (en) | 2025-04-24 |
| CA3074293A1 (en) | 2019-03-14 |
| JP2020533411A (ja) | 2020-11-19 |
| WO2019051100A1 (en) | 2019-03-14 |
| PT3678673T (pt) | 2023-04-24 |
| US20200255863A1 (en) | 2020-08-13 |
| KR102741572B1 (ko) | 2024-12-10 |
| EP4218770A3 (en) | 2023-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3678673T3 (pl) | Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankach | |
| PH12018500719A1 (en) | Oligonucleotide compositions and methods thereof | |
| IL287749A (en) | Compositions for administering implantable drugs and methods of their use | |
| IL256085B (en) | A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| EP3243529A4 (en) | Endonuclease targeting blood coagulation factor viii gene and composition for treating hemophilia comprising same | |
| MX2022009155A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
| MX2021001169A (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. | |
| EP3173074A4 (en) | Composition for delivering bioactive material or protein, and use thereof | |
| IL251503A0 (en) | Single-chain biphasic insulin analogs, preparations containing them and their uses | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| MX2019009149A (es) | Conjugado de material bioactivo que tiene sustentabilidad mejorada y uso del mismo. | |
| PT3782617T (pt) | Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona | |
| EP3151923A4 (en) | Clear compositions and methods for the delivery of active ingredients for skin care | |
| MY174991A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
| MX359181B (es) | Hidrolizado de colágeno y uso del mismo. | |
| IL247099A0 (en) | Beta-converted amino acids and their analogs, preparations containing them and their uses | |
| PL3116514T3 (pl) | Koniugaty oligomeru kwasu hialuronowego lub jego soli, sposób ich wytwarzania i ich zastosowanie | |
| GB2528421A (en) | Methods and processes for application of drug delivery polymeric coatings | |
| SG11201610947UA (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| ZA201706783B (en) | Archaebacteria in bioactive animal feed, method of making the composition and methods employing the composition | |
| IL252683A0 (en) | Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses | |
| LT3658133T (lt) | Kompozicijos, apimančios aminorūgštis, skirtos panaudoti nutukimo gydymui | |
| EP3171858A4 (en) | Method and composition for targeted delivery of therapeutic agents |